Making the Case for a New Analytics Consumption Model

Posted by ZS Editors on Thu, Nov 29, 2018

Industries like retail and technology are transitioning to an AI-driven, personalized approach to surfacing insights to end users, and they’re reaping the benefits. Life sciences companies have the same opportunity to capitalize on the runaway growth in data and rethink the way that analytics are consumed.  

ZS recently partnered with IDC to study how commercial life sciences teams are currently consuming data, and to determine their data and analytics pain points. The study revealed that sales and marketing professionals in life sciences want


>
Read More

From BI to AI: Getting Started With Advanced Analytics

Posted by Niroop Singh on Thu, Nov 01, 2018

Pharmaceutical companies are making big investments in analytics ecosystems, but not without some disappointment in terms of ROI. Because investments are typically limited to people or technology in isolation, companies can’t deliver the kind of value that makes such programs worthwhile. At the same time, cost pressures mean that analytics and data management groups have to deliver more with less. Executives who sponsor such programs also need to be very clear on how to define the success of such initiatives. Creating hundreds of new reports does not equal success. To give your analysts the advanced tools that they need to truly succeed, you need the right combination of people, data processes and technology to get the most out of your advanced analytics investment.

What should my team look like? What kind of processes do I need to support an advanced analytics capability? What kind of technology? These are great questions to ask at the outset, and here are some answers:


>
Read More

New ZS Research on Forecasting in an Evolving Landscape

Posted by Ram Ramakrishnan on Mon, Jul 09, 2018

This post is the second in a four-part series on how pharmaceutical companies can elevate their forecasting operations.

The pharmaceutical industry is facing an increasingly challenging environment with looming biosimilar launches, tighter access and pricing controls, and saturation within primary care markets. Forecasting as a functional area is affected by these changes, given the range of decisions that forecasts inform.


>
Read More

Having Customer-Centric Capabilities Doesn’t Mean That You’re a Customer-Centric Organization

Posted by Pete Mehr on Mon, Jul 02, 2018

This post is the second in a three-part series on how pharma companies can achieve customer centricity.

In my previous blog post, we spoke about pharmaceutical companies moving from a tactic-based marketing process to an orchestrated marketing process. The motivation for making this change is to optimize the customer experience. To achieve this goal, pharmaceutical companies have started to leverage cloud-based computing capabilities, purchase marketing automation platforms, enhance their analytic capabilities using data science and machine learning, use social media platforms, and hire digital experts from other industries, just to name a few of the changes. Yet companies still struggle to realize the value from these investments. 


>
Read More

AI Across the Pond: Implementing Next Best Actions in Europe

Posted by Zainul Jafferji on Wed, Jun 27, 2018

There’s no shortage of news about how artificial intelligence techniques are helping us engage customers better in healthcare. Many pharmaceutical companies have visions of Amazon-like targeting serving up Netflix-esque recommendations on how to engage customers better with the right channels, content and cadence.


>
Read More